Dr. Voorhees on the Future Treatment Paradigm for Myeloma

Peter Voorhees, MD
Published: Tuesday, Aug 11, 2015



Peter Voorhees, MD, associate professor, School of Medicine, UNC-Chapel Hill, Clinical Research, Leukemia, Lymphoma, and Myeloma Program, UNC Lineberger Comprehensive Cancer Center, discusses the future treatment paradigm for myeloma.

With an emergence of monoclonal antibodies, such as daratumumab and elotuzumab, it is likely that these agents will be administered in combination with existing therapies, Voorhees explains. Emerging checkpoint blockade agents are predicted to eradicate minimal residual disease in patients with myeloma.

Voorhees notes that it will be interesting to see if stem cell transplantation will remain a part of the treatment paradigm over the next decade. However, the procedure will likely remain beneficial to eligible patients.



Peter Voorhees, MD, associate professor, School of Medicine, UNC-Chapel Hill, Clinical Research, Leukemia, Lymphoma, and Myeloma Program, UNC Lineberger Comprehensive Cancer Center, discusses the future treatment paradigm for myeloma.

With an emergence of monoclonal antibodies, such as daratumumab and elotuzumab, it is likely that these agents will be administered in combination with existing therapies, Voorhees explains. Emerging checkpoint blockade agents are predicted to eradicate minimal residual disease in patients with myeloma.

Voorhees notes that it will be interesting to see if stem cell transplantation will remain a part of the treatment paradigm over the next decade. However, the procedure will likely remain beneficial to eligible patients.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x